Recent News

• 04.23.2025 - MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation
• 04.16.2025 - MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion
• 04.01.2025 - MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain
• 03.24.2025 - MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development
• 03.04.2025 - MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain
• 12.19.2024 - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company’s Pipeline Development
• 12.10.2024 - MIRA Pharmaceuticals Validates Ketamir-2’s Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Recent Filings

• 04.17.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.16.2025 - 8-K Current report
• 04.15.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 04.11.2025 - 8-K Current report
• 04.01.2025 - 8-K Current report
• 03.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.24.2025 - 8-K Current report
• 03.13.2025 - 8-K Current report
• 03.04.2025 - 8-K Current report